Cover Image

Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study

ABSTRACT: Objective: This study aimed at evaluating the effects of candesartan and ramipril on liver fibrosis in patients with chronic hepatitis C.Methods: This randomized controlled prospective study involved 64 patients with chronic hepatitis C and liver fibrosis. Participants were randomized into...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tarek M. Mostafa (Author), Gamal A. El-azab (Author), Gamal A. Badra (Author), Alyaa S. Abdelwahed (Author), Abeer A. Elsayed (Author)
Format:	Book
Published:	Elsevier, 2021-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CHANGES IN THE PROOXIDATIVE-ANTIOXIDANT SYSTEM IN SHR SERIES RATS WITH TREATMENT OF HYPOTENSIVE MEDICINES (RAMIPRIL AND CANDESARTANE) IN COMBINATION WITH CORVITIN
by: Aliona Marushchak, et al.
Published: (2020)

Protective Role of Ramipril and Candesartan against Myocardial Ischemic Reperfusion Injury: A Biochemical and Transmission Electron Microscopical Study
by: Mohamed Saleem Thattakudian Sheik Uduman, et al.
Published: (2016)

The Effectiveness of 3 Combined Therapeutic Regimens in Egyptian Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Randomized Double-Blind Prospective Pilot Study
by: Tarek M. Mostafa, et al.
Published: (2021)

Morphogenesis of pericellular liver fibrosis in patients with chronic viral hepatitis C associated with hepatic steatosis
by: V. A. Tumanskiy, et al.
Published: (2012)

Liver ultrasound scanning in the detection of hepatic steatosis and fibrosis in NASH patients
by: Mona Hegazy, et al.
Published: (2012)

New diagnostic markers for the degree of liver fibrosis in children with chronic viral hepatitis
by: I. I. Nezgoda, et al.
Published: (2017)

New diagnostic markers for the degree of liver fibrosis in children with chronic viral hepatitis
by: I. I. Nezgoda, et al.
Published: (2017)

Effect of Extracellular Matrix Stiffness on Candesartan Efficacy in Anti-Fibrosis and Antioxidation
by: Tong Zhu, et al.
Published: (2023)

Comparison of the diagnostic efficiency of various noninvasive methods for diagnosing liver fibrosis in patients with chronic viral hepatitis C
by: L. V. Moroz, et al.
Published: (2019)

Comparison of the diagnostic efficiency of various noninvasive methods for diagnosing liver fibrosis in patients with chronic viral hepatitis C
by: L. V. Moroz, et al.
Published: (2019)

A review of Phyllanthus urinaria L. in the treatment of liver disease: viral hepatitis, liver fibrosis/cirrhosis and hepatocellular carcinoma
by: Linhua Liu, et al.
Published: (2024)

Comparative evaluation of the impact of candesartan and ramipril therapy on the levels of GDF 15 and NTproBNP, structural and functional performance of the heart in patients with coronary artery disease with asymptomatic diastolic dysfunction after myocar
by: V. D. Syvolap, et al.
Published: (2014)

Protective Effect of Co Q10 and Candesartan on Bleomyycin Induced Lung Fibrosis in Rats
by: Fatima Mohammad Saeed Mahdi, et al.
Published: (2022)

Functional candesartan loaded lipid nanoparticles for the control of diabetes-associated stroke: In vitro and in vivo studies
by: Dina M. Mahmoud, et al.
Published: (2024)

Biorelevant dissolution of candesartan cilexetil
by: Lucie Gruberová, et al.
Published: (2017)

Value of serum fibronectin for assessment of liver fibrosis in chronic hepatitis C virus patients
by: Ahmed A Ghafar, et al.
Published: (2019)

Viral hepatitis in children: state and prospects for solving the problem
by: L. G. Goriacheva, et al.
Published: (2021)

THE NEW FIXED COMBINATION OF AMLODIPINE AND RAMIPRIL IN THE TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2015)

THE NEW FIXED COMBINATION OF AMLODIPINE AND RAMIPRIL IN THE TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2015)

Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations
by: Lingfeng Guo, et al.
Published: (2023)

The comparison between combination of candesartan-amlodipine and candesartan-furosemide on blood pressure in hypertensive patients with chronic kidney disease
by: Dian Ayu Juwita, et al.
Published: (2022)

CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRIL
by: D. A. Napalkov, et al.
Published: (2016)

CARDIOPROTECTIVE AND NEPHROPROTECTIVE EFFECTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITOR RAMIPRIL
by: D. A. Napalkov, et al.
Published: (2016)

Prospective therapeutics for intestinal and hepatic fibrosis
by: Xin Li, et al.
Published: (2023)

RAMIPRIL EFFICACY IN PATIENTS WITH ARTERIAL HYPERTENSION AND ISCHEMIC HEART DISEASE
by: A. I. Chesnikova, et al.
Published: (2016)

RAMIPRIL IN THERAPY OF PATIENTS AFTER MYOCARDIAL INFARCTION
by: I. V. Szirov, et al.
Published: (2015)

RAMIPRIL IN THERAPY OF PATIENTS AFTER MYOCARDIAL INFARCTION
by: I. V. Szirov, et al.
Published: (2015)

Development of Methods of Quality Control of the Tablets «Ramipril»
by: Kateryna Typlynska, et al.
Published: (2023)

Morphological and ultrasound features of liver fibrosis in children with autoimmune hepatitis
by: V. S. Berezenko, et al.
Published: (2018)

One Life, One Liver - Toward the elimination of viral hepatitis
by: Dilini Mataraarachchi
Published: (2023)

50th International Liver Congress: update on viral hepatitis
by: Morven Cunningham, et al.
Published: (2015)

Novel Combination for Self-Nanoemulsifying Drug Delivery System of Candesartan Cilexetil
by: Safa F. Mekhilef, et al.
Published: (2018)

EFFECT OF ANTIVIRAL THERAPY ON CARDIOHEMODYNAMIC INDICATORS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS AND LIVER CIRRHOSIS
by: M. V. Chistyakova, et al.
Published: (2017)

EXPERIENCE OF RAMIPRIL (HARTIL) USAGE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK (THE OPTIMIST STUDY)
by: I. A. Velizhanina, et al.
Published: (2016)

EXPERIENCE OF RAMIPRIL (HARTIL) USAGE IN PATIENTS WITH HIGH CARDIOVASCULAR RISK (THE OPTIMIST STUDY)
by: I. A. Velizhanina, et al.
Published: (2016)

Beneficial Effect of Candesartan on Rat Diastolic Heart Failure
by: Ryotaro Wake, et al.
Published: (2005)

Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure
by: Imad Kassem, et al.
Published: (2021)

A Liver Biopsy Validation Pilot Study of Shear Wave Elastography, APRI, FIB-4, and Novel Serum Biomarkers for Liver Fibrosis Staging in Children With Chronic Viral Hepatitis
by: Rebecca Mercedes MD, et al.
Published: (2020)

COMPARISON OF NEW GENERIC AND ORIGINAL RAMIPRIL IN PATIENTS WITH ARTERIAL HYPERTENSION AND HIGH CARDIOVASCULAR RISK
by: S. Yu. Martsevich, et al.
Published: (2016)

Liver histology in patients on hemodialysis with chronic hepatitis C viral infection
by: Mysorekar Vijaya, et al.
Published: (2008)